Adia Nutrition gets IRB approval for stem cell trial in chronic kidney disease patients

Adia Nutrition announced that its pivotal clinical study on chronic kidney disease (CKD) has received Institutional Review Board (IRB) approval and has been submitted to ClinicalTrials.gov. The study will evaluate the safety and efficacy of Adia's proprietary AdiaVita stem cell and exosome therapy derived from umbilical cord blood in adults with moderate to advanced CKD. This randomized controlled trial aims to track kidney function and inflammation markers to provide clinical data supporting stem cell therapy in kidney disease management. Recruitment will begin soon, marking a key step in advancing regenerative treatments for CKD.